Clairity Raises $43 Million in Series B to Launch First FDA-Authorized AI Platform for Breast Cancer Risk Prediction
Clairity, Inc., an AI-driven precision health company pioneering image-based risk prediction, today announced the closing of a $43 million Series B financing. The funds will be used to commercialize the company’s product, Clairity Breast, the first FDA-authorized artificial intelligence platform that predicts a woman’s five-year risk of breast cancer directly from a routine mammogram, and to advance development of Clairity Breast 3D and Clairity Heart, Clairity’s next offering focused on predicting cardiovascular risk from the same routine imaging exam.
Clairity Showcases Demonstration of CLAIRITY BREAST on NBC’s TODAY Show
Clairity, Inc., advancing AI-powered human health solutions, today announced a demonstration of its FDA-authorized CLAIRITY BREAST platform on NBC’s TODAY Show. The segment featured NBC anchor Savannah Sellers, who provided her mammogram images for analysis by the CLAIRITY BREAST AI platform for educational and informational purposes. Dr. Connie Lehman, Clairity’s founder, discussed the resulting five-year breast cancer risk estimate with Sellers during the broadcast.
Clairity Founder Dr. Connie Lehman Named to Forbes 50 Over 50 Innovation List
Clairity, Inc., a company pioneering AI-powered risk prediction in human health, today announced that Founder Dr. Connie Lehman has been named to the Forbes “50 Over 50: Innovation” list. This annual ranking celebrates women who are breaking boundaries and advancing bold solutions to global challenges. Dr. Lehman will be honored at the Forbes & Mika Brzezinski 50 Over 50 Celebration on November 4, 2025, in New York City.
Clairity CEO, Jeff Luber, Presenting at BIO International Convention 2025
Clairity, Inc., advancing AI-powered human health solutions, today announced that members of its executive leadership team will be attending and participating in the upcoming BIO International Convention 2025, taking place June 16-19, 2025 in Boston, with its CEO, Jeff Luber, presenting the company update.
ADDING MULTIMEDIA Clairity Becomes the First FDA-Authorized AI Platform for Breast Cancer Prediction – Historic Milestone for Women’s Health
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025 – propelling a new era of precision medicine in breast cancer.
